News & Events

Developing a rapid multi-omic liquid biopsy blood test utilising whole genome sequencing to resolve the difficult diagnosis of cancer of unknown primary origin.

Establishing a comprehensive patient dataset of inherited retinal diseases, providing information to drive new treatments and therapies for the most common cause of blindness in working-aged Australians.

A trial using genomic testing and predictive disease modelling to guide therapy and reduce the burden of prostate cancer diagnosis, which evidence suggests is over-diagnosed and over-treated in early disease.

Precision medicine allows us to develop treatments for a specific disease in one person. But we must ensure all Australians can access these benefits

TAGC was proud to sponsor the University of Melbourne’s annual MDHS Honours Conference this year, in line with the partnership’s commitment to supporting scholarship and learning opportunities to equip the next generation of researchers with the skills to lead the genomic workforce of the future.

The TAGC team recently received full diagnostic accreditation through the National Association of Testing Authorities (NATA) to perform ‘ctDNA profiling’ analysing tumour DNA collected via liquid biopsy. It’s a crucial step towards making advanced genomics testing more affordable and accessible.